Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights
Katherine Campbell,Akhil Muthigi,Armin Ghomeshi,Kyle Schuppe,Max D Sandler,Ranjith Ramasamy
DOI: https://doi.org/10.2147/DHPS.S383130
2023-04-01
Drug, Healthcare and Patient Safety
Abstract:Katherine Campbell, 1 Akhil Muthigi, 1 Armin Ghomeshi, 2 Kyle Schuppe, 3 Max D Sandler, 4 Ranjith Ramasamy 1 1 Desai Sethi Urology Institute, University of Miami, Miami, Fl, 33136, USA; 2 Herbert Wertheim College of Medicine, Florida International University, Miami, FL, 33199, USA; 3 Washington State University Elson S. Floyd College of Medicine, Spokane, WA, 99202-2131, USA; 4 University of Miami Miller of Medicine, Miami, Fl, USA Correspondence: Ranjith Ramasamy, Desai Sethi Urology Institute, University of Miami, 1120 NW 14th St, Miami, Fl, 33136, USA, Tel +1 305-243-6090, Email Testosterone deficiency is diagnosed by a serum total testosterone level below 300 ng/dL in combination with symptoms such as decreased energy and libido. These symptoms can be ameliorated by restoring serum testosterone to the physiologic range with testosterone therapy (TT). There are numerous forms of testosterone therapy, such as injectable, transdermal, nasal, and subcutaneous applications. There are also multiple formulations of injection, such as testosterone cypionate, testosterone enanthate, and testosterone undecanoate. Testosterone undecanoate (TU) is a long-acting ester formulation of testosterone that can be provided in an injectable or oral form. Oral testosterone undecanoate is marketed as Andriol, Jatenzo, Tlando, and Kyzatrex. Oral TU provides a convenient option for many patients, which may increase compliance with TT. Injectable testosterone undecanoate is marketed as Aveed and Nebido. Injectable TT remains the most cost-effective therapeutic option and is appropriate for most patients as an initial therapy. This review describes the pharmacokinetics of these testosterone undecanoate products and provides a guide for prescribers using these medications. While many forms of testosterone are appropriate for TT, a patient-centered discussion focused on goals of care should best guide physician prescription of these medications. Keywords: testosterone, testosterone deficiency, testosterone therapy, hypogonadism in male Testosterone deficiency is recognized as the deficiency of testosterone (T) production by the testes. This deficiency results in a pathologically low systemic testosterone concentration, as well as the concentrations of its bioactive metabolites dihydrotestosterone (DHT) and estradiol (E2). 1 Testosterone deficiency may affect up to 10% of men worldwide and 40% of men over the age of 45. 2,3 Signs and symptoms of testosterone deficiency include characteristic physical changes such as regression of secondary sex characteristics, decreased lean muscle mass, and cognitive changes. 3–5 The restoration of serum testosterone to physiologic, or eugonadal, levels has been shown to alleviate some of the symptoms of testosterone deficiency and provide significant improvement in quality of life. 6 Multiple treatment options for testosterone deficiency exist, most commonly consisting of testosterone therapy (TT) with exogenous testosterone. Specifically, testosterone undecanoate (TU) is an 11-carbon long androgen ester derivative of testosterone that comes in an injectable or oral formulation. Recently, we have seen a rapid increase in the available FDA-approved TU forms of T. Herein, we present a focused review on testosterone undecanoate and its various formulations, as well as a practical guide for prescribers. As per American Urologic Association guidelines, testosterone deficiency is diagnosed with a serum testosterone level below 300 ng/dL on two separate occasions, with both conducted in the early morning in combination with symptoms. 7 Recent studies suggest that 300 ng/dL may not be an appropriate cutoff for diagnosis of testosterone deficiency, and thus the diagnosis should be made by a trained physician based on serum biochemical (testosterone and sex hormone binding globulin) and clinical symptoms given the specific patient's concomitant medical conditions. 8 Regardless of primary or secondary etiology, testosterone deficiency is associated with characteristic physical changes, including gynecomastia, regression of secondary sex characteristics, and sexual dysfunction. 5,7 Testosterone deficiency is also associated with musculoskeletal changes such as decreased bone mineral density and muscle mass. 5 In addition, obese or overweight men have been shown to have higher rates of secondary testosterone deficiency than their normal weight counterparts. 9 Psychological disturbances such as low motivation, poor concentration, and diminished energy are also frequent concerns of men with low T. 5,10 Of the symptoms, diminished energy is the most reported hypogonadal symptom in men younger than 40 years o -Abstract Truncated-